[{"orgOrder":0,"company":"Mabion SA","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mabion SA \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Novavax"}]

Find Clinical Drug Pipeline Developments & Deals by Mabion SA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Upon Mabion’s successful production of the technical batches, the parties may enter into a broader contract for the production of antigen for NVX-CoV2373 for commercial use, should it be approved by regulatory agencies.

                          Product Name : Nuvaxovid

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 03, 2021

                          Lead Product(s) : NVX-COV2373,Matrix-m1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Novavax

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank